Slavov Receives NIH Director’s New Innovator Award

Slavov Receives NIH Director’s New Innovator Award

BioE Assistant Professor Nikolai Slavov was awarded the National Institutes of Health Director’s New Innovator Award and a $2.35M grant to study “Ribosome-Mediated Translational Regulation during Stem Cell Differentiation“.


Source: News @ Northeastern

Direct evi­dence. It’s the holy grail in sci­en­tific discovery.

Nikolai Slavov, assis­tant pro­fessor in the Depart­ment of Bio­engi­neering, found that grail in the least likely of places: deep inside ribo­somes, the mol­e­c­ular machines in cells that assemble all the pro­teins that keep living things—from bud­ding yeast to us—functioning.

This month, the National Insti­tutes of Health rec­og­nized Slavov’s ground­breaking research with its Director’s New Inno­vator Award. The five-​​year, $2.35 mil­lion award is part of the NIH Common Fund’s High-​​Risk, High-​​Reward Research pro­gram, which sup­ports highly cre­ative early-​​career researchers taking out-​​of-​​the-​​box approaches to major chal­lenges in bio­med­ical research.

Slavov’s work flew in the face of sci­en­tists’ decades-​​long assump­tion that all ribo­somes were the same. Some spec­u­lated that their com­po­si­tion, and hence their func­tion, might vary, but no one had been able to pro­vide exper­i­mental or obser­va­tional proof of the claim.

Ribo­somes are one of the most fun­da­mental and highly con­served struc­tures in biology. Our work could help reshape our under­standing of a cen­tral tenet of the field: how infor­ma­tion from genes is reg­u­lated.
—Nikolai Slavov, assis­tant professor

Until, that is, Slavov and his col­leagues revealed the dis­par­i­ties in full-​​color schematics last year in a paper pub­lished in the journal Cell Reports. The con­cept of “spe­cial­ized ribosomes”—that not all ribo­somes house the same stan­dard 80 core pro­teins but rather vari­eties of them—had finally been val­i­dated. The find­ings could have impli­ca­tions for new direc­tions in fields from cancer ther­a­peu­tics to regen­er­a­tive medicine.

Ribo­somes are one of the most fun­da­mental and highly con­served struc­tures in biology,” says Slavov. “The grant will enable me to inves­ti­gate the spe­cial­ized ribo­some hypoth­esis fur­ther and flush out how the ribo­somes’ varying com­po­si­tions affect their bio­log­ical func­tion. Our work could help reshape our under­standing of a cen­tral tenet of the field: how infor­ma­tion from genes is regulated.”

Upending con­ven­tional wisdom

Before Slavov’s dis­covery, sci­en­tists believed that ribo­somes in unper­turbed cells had a pas­sive role in the expres­sion of genetic infor­ma­tion. A mol­e­cule called mes­senger RNA, or mRNA, picked up protein-​​assembly instructions—which amino acids to link in a chain and in what order they should link—from genes and deliv­ered them to the ribo­some to follow.

10/21/15 - BOSTON, MA. - Nikolai Slavov poses for a portrait in Egan on Oct. 21, 2015. Photo by Adam Glanzman/Northeastern University

Nikolai Slavov, assis­tant pro­fessor in the Depart­ment of Bio­engi­neering Photo by Adam Glanzman/​Northeastern University

Slavov’s find­ings, how­ever, indi­cated that ribo­somes not only assem­bled pro­teins, they also appeared to reg­u­late that pro­duc­tion. In a sense, a fac­tory line worker had now become a plant foreman. Ribo­somes may deter­mine, for example, how many and which types of pro­teins will be made in spe­cific tissues.

The poten­tial appli­ca­tions are broad. In tissue engi­neering, for example, if researchers want to pro­gram, say, an embry­onic stem cell to make a heart cell, they may now have to take into account how to influ­ence the ribo­some. If a genetic muta­tion has led to a core-​​protein mal­func­tion that con­tributes to the growth of cancer, researchers may now con­sider devel­oping drugs that target that ribo­somal core pro­tein to restore its func­tion, inhibiting cancer growth.

The award sup­ports basic research—those appli­ca­tions are in the future,” says Slavov. “But con­tinued val­i­da­tion of my spe­cial­ized ribo­somes hypoth­esis could one day directly sug­gest rational ther­a­pies for can­cers such as glioblas­toma, which cur­rently doesn’t have any effec­tive treatment.”

‘Northeastern’s spirit of boldness’

To dive into the inner-​​workings of the ribo­some, Slavov used the most sophis­ti­cated mass-​​spectrometry tech­niques to ana­lyze the core pro­teins in ribo­somes from both bud­ding yeast cells and mouse embry­onic stem cells. Exploring such dis­sim­ilar cell types per­mitted him to gen­er­alize his results.

There is this momentum and enthu­siasm for taking smart risks among both the fac­ulty and stu­dents at Northeastern—asking big ques­tions and doing what­ever is required to con­tribute to their res­o­lu­tion.
—Nikolai Slavov, assis­tant professor

With the award from the NIH, Slavov will con­tinue honing his tools of the trade, inventing low-​​cost, high-​​throughput ways to directly mea­sure ribo­somes’ rate of pro­tein syn­thesis and accu­rately quan­tify and dis­tin­guish their core pro­teins from one another, regard­less of how sim­ilar those pro­teins may appear.

As the award attests, Slavov has come a long way in his short time at North­eastern. He joined the fac­ulty last fall and now has three grad­uate stu­dents and five under­grad­u­ates in his lab accom­pa­nying him on his journey inside the cell’s remark­able protein-​​synthesizing machinery. He credits the university’s entre­pre­neurial vision as instru­mental in his rapid progress.

The university’s spirit of bold­ness is very much aligned with this award,” he says. “There is this momentum and enthu­siasm for taking smart risks among both the fac­ulty and stu­dents at Northeastern—asking big ques­tions and doing what­ever is required to con­tribute to their resolution.”

Related Faculty: Nikolai Slavov

Related Departments:Bioengineering